高影响力试验中遗传与组学信息聚焦癌症突变、由产业资助且透明度较低
该meta-研究评估2019至2022年600项被引最多的临床试验中遗传与组学信息的使用情况。132项(22%)试验使用了遗传或组学信息,主要用于癌症突变检测(n=101)。产业资助占84.0%,肿瘤试验更倾向产业资助并偏好产业干预,透明度有限。
要点
- 132项(22%)高被引试验使用遗传或组学信息,其中101项用于癌症突变检测。
- 多数(84.0%)由产业资助,肿瘤试验产业资助比例更高(90.1% vs 64.5%)。
- 遗传与组学试验较其他试验更易受产业资助(84% vs 63.9%),完整方案和统计计划可得性更低。
核心结论
- 研究强调当前遗传与组学技术除癌症突变检测外利用不足,产业参与更显著且透明度更有限,引发对潜在偏倚的担忧。
研究设计与样本
- meta-研究评估,使用先前构建的2019至2022年发表的600项被引最多的临床试验数据库,纳入在试验设计、分析及结果中利用参与者遗传或组学特征的试验。
主要发现
- 132项(22%)试验使用了遗传或组学信息,主要用于检测癌症突变(n=101)。
- 利用方式包括纳入标准(n=59)、亚组分析(n=82)和随机化分层因素(n=14)。
- 82项研究(62%)在结论中讨论了相关性。
- 102项研究(77%)提供数据可得性声明,其中6项数据已可得。
- 多数研究由产业资助(n=111 [84.0%])。
关键数值与推荐
- 132项(22%)试验使用遗传或组学信息,癌症突变检测n=101。
- 产业资助n=111(84.0%);肿瘤试验产业资助90.1% vs 非肿瘤64.5%(P = .001)。
- 肿瘤试验产业附属分析师43.6% vs 22.6%(P = .036);偏好产业赞助干预83.2% vs 58.1%(P = .004)。
- 遗传与组学试验产业资助84% vs 其他试验63.9%(P < .001);完整方案可得性P = .018,统计计划可得性P = .04。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess how genetics and -omics information is used in the most cited recent clinical trials and to evaluate industry involvement and transparency patterns. STUDY DESIGN AND SETTING: This is a meta-research evaluation using a previously constructed database of the 600 most cited clinical trials published from 2019 to 2022. Trials that utilized genetic or -omics characterization of participants in the trial design, analysis, and results were considered eligible. RESULTS: 132 (22%) trials used genetic or -omics information, predominantly for detection of cancer mutations (n = 101). Utilization included eligibility criteria (n = 59), subgroup analysis (n = 82), and stratification factor in randomization (n = 14). Authors addressed the relevance in the conclusions in 82 studies (62%). 102 studies (77%) provided data availability statements and six had data already available. Most studies had industry funding (n = 111 [84.0%]). Oncology trials were more likely to be industry-funded (90.1% vs 64.5%, P = .001), to have industry-affiliated analysts (43.6% vs 22.6%, P = .036), and to favor industry-sponsored interventions (83.2% vs 58.1% P = .004). When compared to other trials, genetic and -omics trials were more likely to be funded by industry (84% vs 63.9%, P < .001) and tended to be less likely to have full protocols (P = .018) and statistical plans (P = .04) available. CONCLUSION: Our study highlights the current underutilization of genetic and -omics technologies beyond testing for cancer mutations. Industry involvement in these trials appears to be more substantial and transparency is more limited, raising concerns about potential bias.
引用
- Russo L, Siena LM, Farina S, et al. High-impact trials with genetic and -omics information focus on cancer mutations, are industry-funded, and less transparent. J Clin Epidemiol. 2025. PMID: 39826627. doi:10.1016/j.jclinepi.2025.111676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。